Deals in Depth: September 2011
After out-licensing the Alzheimer’s candidate several years ago, Roche took back rights to Evotec’s EVT302 in an alliance worth $180 million. Perkin Elmer paid $577 million in cash for Caliper Life Sciences, which produces molecular imaging and detection technologies. Both biopharma and medical device financing increased in September vs. August.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.